Kiora Pharmaceuticals Management
Management criteria checks 4/4
Kiora Pharmaceuticals' CEO is Brian Strem, appointed in Jul 2021, has a tenure of 3.33 years. total yearly compensation is $802.27K, comprised of 51.9% salary and 48.1% bonuses, including company stock and options. directly owns 1.01% of the company’s shares, worth $101.61K. The average tenure of the management team and the board of directors is 3.1 years and 3.6 years respectively.
Key information
Brian Strem
Chief executive officer
US$802.3k
Total compensation
| CEO salary percentage | 51.9% |
| CEO tenure | 3.3yrs |
| CEO ownership | 1.0% |
| Management average tenure | 3.1yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem
May 21
Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
Oct 13Kiora Pharma announces 1-for-40 reverse stock split
Sep 26Kiora Pharmaceuticals reports 1H results
Aug 12Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing
Jul 28Kiora Pharmaceuticals prices $5.2M underwritten public offering
Jul 22Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201
Jul 05EyeGate Pharmaceuticals announces $8M private placement
Jan 06EyeGate surge in premarket as it acquires Panoptes Pharma for $4M
Dec 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$6m |
| Jun 30 2024 | n/a | n/a | US$3m |
| Mar 31 2024 | n/a | n/a | US$2m |
| Dec 31 2023 | US$802k | US$416k | -US$13m |
| Sep 30 2023 | n/a | n/a | -US$13m |
| Jun 30 2023 | n/a | n/a | -US$12m |
| Mar 31 2023 | n/a | n/a | -US$12m |
| Dec 31 2022 | US$714k | US$400k | -US$14m |
| Sep 30 2022 | n/a | n/a | -US$17m |
| Jun 30 2022 | n/a | n/a | -US$15m |
| Mar 31 2022 | n/a | n/a | -US$15m |
| Dec 31 2021 | US$659k | US$169k | -US$14m |
Compensation vs Market: Brian's total compensation ($USD802.27K) is about average for companies of similar size in the US market ($USD649.07K).
Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.
CEO
Brian Strem (44 yo)
3.3yrs
Tenure
US$802,274
Compensation
Dr. Brian M. Strem, Ph D., is Co-Founder and Director at Okogen, Inc. He served as Principal Financial and Accounting Officer of Kiora Pharmaceuticals, Inc. since June 16, 2022. He serves as President, Dir...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.3yrs | US$802.27k | 1.01% $ 101.6k | |
| Chief Financial Officer | 2.2yrs | US$387.48k | 0.45% $ 45.8k | |
| Chief Development Officer | 3.1yrs | US$652.31k | 0.62% $ 62.6k | |
| Executive Vice President of CMC & Operations | no data | no data | no data |
3.1yrs
Average Tenure
44yo
Average Age
Experienced Management: KPRX's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.3yrs | US$802.27k | 1.01% $ 101.6k | |
| Independent Director | less than a year | no data | 0.042% $ 4.2k | |
| Member of Scientific Advisory Board | 7.7yrs | no data | no data | |
| Independent Chairman of the Board | 16.4yrs | US$98.25k | 0.17% $ 16.9k | |
| Member of Scientific Advisory Board | 7.1yrs | no data | no data | |
| Director | 3.6yrs | US$70.12k | 0.10% $ 10.1k | |
| Member of Scientific Advisory Board | 6.8yrs | no data | no data | |
| Independent Director | 2.9yrs | US$77.62k | 0% $ 0 | |
| Non-Employee Independent Director | 2.8yrs | US$84.50k | 0.18% $ 17.7k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
3.6yrs
Average Tenure
53yo
Average Age
Experienced Board: KPRX's board of directors are considered experienced (3.6 years average tenure).